Review



dynamic pbpk modeling software gastroplustm version 9.9  (Simulations Plus Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Simulations Plus Inc dynamic pbpk modeling software gastroplustm version 9.9
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Dynamic Pbpk Modeling Software Gastroplustm Version 9.9, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/pbpk+model+commercial+software+gastroplus/pmc11983545-113-16-23
    Average 90 stars, based on 1 article reviews
    dynamic pbpk modeling software gastroplustm version 9.9 - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis"

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2025.1555276

    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Figure Legend Snippet: Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Techniques Used: Concentration Assay, Clinical Proteomics

    The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.
    Figure Legend Snippet: The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Techniques Used: Clinical Proteomics

    Related Articles

    other:

    Article Title: Physiologically based pharmacokinetic (PBPK) modelling of oral drug absorption in older adults - an AGePOP review.
    Article Snippet: Another PBPK platform is GastroPlus (Simulations Plus, Inc., Lancaster, California) wherein the Population Estimates for Age-Related (PEARTM) PhysiologyTM module accounts for the body weight, height, body mass index, tissue weights and volumes, and tissue perfusion rates in older adults (SimulationsPlus.

    Article Title: Prediction of the exposure profile of bisphenol A in Chinese population by physiologically-based pharmacokinetics modeling.
    Article Snippet: 29 Bisphenol A (BPA) has emerged as a typical contaminant which can induce various 30 adverse effects on human health and environment.. BPA exposure and the corresponding 31 human responses can vary across different regions and populations.. China is one of the 32 largest producers and consumers of BPA, but the exposure profile of BPA in Chinese 33 population is poorly understood.

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis
    Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

    Article Title: Effect of Food and a Proton-Pump Inhibitor on the Absorption of Encorafenib: An In Vivo – In Vitro – In Silico Approach
    Article Snippet: Simulations were performed using the commercially available PBPK modeling platform GastroPlus 9.8 (Simulations Plus, Inc., Lancaster, CA).

    Article Title: In Vitro-In Vivo Relationship in Mini-Scale-Enabling Formulations of Corallopyronin A.
    Article Snippet: Plasma concentration-time profiles for CorA-povidone and CorA-copovidone ASD formulations were simulated using the PBPK modeling software GastroPlusTM 9.8 (Simulations Plus, Inc., 2020).

    Software:

    Article Title: PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
    Article Snippet: .. PBPK modeling and simulation software GastroPlusTM version 9.5 (Simulations Plus Inc., Lancaster, CA, USA) was used for the prediction of PK parameters and generation of simulated human plasma concentration profiles. ..

    Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets
    Article Snippet: .. The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA). ..

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling
    Article Snippet: .. All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA). ..

    Clinical Proteomics:

    Article Title: PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
    Article Snippet: .. PBPK modeling and simulation software GastroPlusTM version 9.5 (Simulations Plus Inc., Lancaster, CA, USA) was used for the prediction of PK parameters and generation of simulated human plasma concentration profiles. ..

    Concentration Assay:

    Article Title: PBPK Modeling and Simulation of Antibiotics Amikacin, Gentamicin, Tobramycin, and Vancomycin Used in Hospital Practice
    Article Snippet: .. PBPK modeling and simulation software GastroPlusTM version 9.5 (Simulations Plus Inc., Lancaster, CA, USA) was used for the prediction of PK parameters and generation of simulated human plasma concentration profiles. ..

    Extraction:

    Article Title: From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus ® -Driven Framework for Generic Candesartan Cilexetil Tablets
    Article Snippet: .. The PBPK model of candesartan cilexetil was developed using commercially available PBPK modeling software GastroPlus ® (version 9.5, Simulations Plus, Inc., Lancaster, CA, USA) and Digit literature data extraction software (version 1.0.4, Simulation Plus, Inc., Lancaster, CA, USA). ..

    In Vivo:

    Article Title: In Vitro and In Vivo Bioequivalence Study of 3D-Printed Instant-Dissolving Levetiracetam Tablets and Subsequent Personalized Dosing for Chinese Children Based on Physiological Pharmacokinetic Modeling
    Article Snippet: .. All in vivo PK simulations in this study were performed in the PBPK model commercial software GastroPlus (Version 9.8, Simulations Plus, Inc., Lancaster, PA, USA). ..



    Similar Products

    90
    Simulations Plus Inc gastroplustm software
    Gastroplustm Software, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/gastroplustm+software/pm40281717-76-0-7
    Average 90 stars, based on 1 article reviews
    gastroplustm software - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Simulations Plus Inc gastroplustm software version 9.8.2000
    Gastroplustm Software Version 9.8.2000, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/gastroplustm+software/pmc12024831-124-0-4
    Average 90 stars, based on 1 article reviews
    gastroplustm software version 9.8.2000 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Simulations Plus Inc dynamic pbpk modeling software gastroplustm version 9.9
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Dynamic Pbpk Modeling Software Gastroplustm Version 9.9, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/pbpk+model+commercial+software+gastroplus/pmc11983545-113-16-23
    Average 90 stars, based on 1 article reviews
    dynamic pbpk modeling software gastroplustm version 9.9 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Simulations Plus Inc pbpk modeling software gastroplustm version 9.8.2
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Pbpk Modeling Software Gastroplustm Version 9.8.2, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/pbpk+model+commercial+software+gastroplus/pm40122328-71-52-59
    Average 90 stars, based on 1 article reviews
    pbpk modeling software gastroplustm version 9.8.2 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Simulations Plus Inc gastroplustm software version 9.7
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Gastroplustm Software Version 9.7, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/gastroplustm+software/pmc11897275-155-20-24
    Average 90 stars, based on 1 article reviews
    gastroplustm software version 9.7 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Simulations Plus Inc gastroplustm software version 9.6
    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and <t>PBPK</t> model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.
    Gastroplustm Software Version 9.6, supplied by Simulations Plus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gastroplustm+software/gastroplustm+software/pmc11279950-150-10-14
    Average 90 stars, based on 1 article reviews
    gastroplustm software version 9.6 - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Journal: Frontiers in Pharmacology

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    doi: 10.3389/fphar.2025.1555276

    Figure Lengend Snippet: Model simulations of vancomycin concentration-time profiles from four studies in the training dataset: (A) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young US population. (B) Observed and PBPK model simulated vancomycin plasma concentrations after a single 1,000 mg intravenous dose in a young Chinese population. (C) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the HC group. (D) Observed and PBPK model simulated vancomycin plasma concentrations after multiple 1,000 mg doses every 12 h in the LC group.

    Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

    Techniques: Concentration Assay, Clinical Proteomics

    The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Journal: Frontiers in Pharmacology

    Article Title: High vs. low vancomycin therapeutic concentrations in periprosthetic joint infection: A retrospective cohort analysis

    doi: 10.3389/fphar.2025.1555276

    Figure Lengend Snippet: The model to predict vancomycin concentrations in the red marrow, yellow marrow and kidney: (A) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the HC group. (B) Observed and PBPK model simulated concentrations in plasma, red marrow, and yellow marrow in the LC group. (C) Observed and PBPK model simulated concentrations in plasma and kidney in the HC group. (D) Observed and PBPK model simulated concentrations in plasma and kidney in the LC group.

    Article Snippet: To assess pharmacokinetics and tissue distribution of vancomycin in PJI patients, we employed the commercially available dynamic PBPK modeling software GastroPlusTM version 9.9 (Simulations Plus, Inc.) to construct a stepwise model as previously described ( ).

    Techniques: Clinical Proteomics